HUTCHMED (China) (HCM) Net Income towards Common Stockholders (2015 - 2021)
HUTCHMED (China) (HCM) reported Net Income towards Common Stockholders of -$77.6 million for Q2 2021, down 551.86% year-over-year from $17.2 million in Q2 2020, and down 27.31% quarter-over-quarter from -$61.0 million in Q1 2021.
HUTCHMED (China) (HCM) Net Income towards Common Stockholders (2015 - 2021) Analysis & Trends
HUTCHMED (China) (HCM) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$77.6 million in Q2 2021.
- Net Income towards Common Stockholders for Q2 2021 came in at -$77.6 million, down 551.86% year-over-year; the trailing twelve-month figure through Dec 2022 was -$77.6 million (up 43.99% YoY), and the FY2025 annual result was $64.4 million, up 8132.64% from the prior year.
- Net Income towards Common Stockholders retreated to -$77.6 million in Q2 2021 per HCM's latest filing, from -$61.0 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $70.1 million in Q2 2018 and troughed at -$99.4 million in Q2 2019.
- A 4-year average of -$17.2 million and a median of -$26.3 million in 2018 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2019 and 2021: Net Income towards Common Stockholders jumped 250.63% in 2019, then sank 551.86% in 2021.
- A 4-year view of Net Income towards Common Stockholders shows it stood at $22.1 million in 2018, then tumbled by 270.87% to -$37.8 million in 2019, then jumped by 145.5% to $17.2 million in 2020, then slumped by 551.86% to -$77.6 million in 2021.
- Business Quant data shows HCM's Net Income towards Common Stockholders at -$77.6 million in Q2 2021, -$61.0 million in Q1 2021, and $17.2 million in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -92.12 Mn |
| 10 | HUTCHMED (China) | 1.20 Bn | -269.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -77.62 Mn |
| Mar 31, 2021 | -60.97 Mn |
| Jun 30, 2020 | 17.18 Mn |
| Mar 31, 2020 | -30.28 Mn |
| Dec 31, 2019 | -37.75 Mn |
| Sep 30, 2019 | -34.24 Mn |
| Jun 30, 2019 | -99.44 Mn |
| Mar 31, 2019 | 33.60 Mn |
| Dec 31, 2018 | 22.09 Mn |
| Sep 30, 2018 | 12.78 Mn |
| Jun 30, 2018 | 70.12 Mn |
| Mar 31, 2018 | -22.31 Mn |
| Jun 30, 2016 | 85.09 Mn |
| Jun 30, 2015 | 70.55 Mn |